ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 092,11
-0,61%
Dow Jones
39 740,09
-0,33%
DAX
18 680,20
-0,25%
Brent Oil
81,97
-0,58%
Bitcoin
69 761,86
-0,51%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. 60 Degrees Pharmaceuticals Inc (SXTP)

  7. 60 Degrees Pharmaceuticals Inc (SXTP) Actualités

SXTP 60 Degrees Pharmaceuticals Inc

0,284
0,0049 (1,76%)
Dernière mise à jour : 19:27:59
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
60 Degrees Pharmaceuticals Inc SXTP NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,0049 1,76% 0,284 19:27:59
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,29 0,2701 0,3005 0,2791
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
20/5/202413:59GLOBE60 Degrees Pharmaceuticals Funds Babesia spp Testing in..
15/5/202419:45GLOBE60 Degrees Pharmaceuticals Announces First Quarter 2024..
08/5/202413:59GLOBE60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial..
02/5/202413:59GLOBE60 Degrees Pharmaceuticals Receives FDA Comments on..
03/4/202413:58GLOBE60 Degrees Pharmaceuticals to Sponsor Pilot Study of..
14/3/202412:59GLOBE60 Degrees Pharmaceuticals Announces Communication from the..
20/2/202422:00EDGAR2Form 8-K - Current report
20/2/202413:59GLOBE60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies..
08/2/202413:59GLOBE60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief..
02/2/202421:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202421:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202418:00PRNUSWallachBeth Capital Announce Closing of 60 Degrees..
31/1/202417:15GLOBE60 Degrees Pharmaceuticals Announces Closing of $2.4 Million..
30/1/202415:45PRNUSWallachBeth Capital Announces Pricing of 60 Degrees..
30/1/202415:00GLOBE60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million..
30/1/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
22/1/202423:01EDGAR2Form 8-K - Current report
22/1/202413:59GLOBE60 Degrees Pharma Plans Pivotal Babesiosis Study with..
16/1/202420:56EDGAR2Form 8-K - Current report
16/1/202413:59GLOBE60 Degrees Pharma Regains Compliance with Nasdaq Listing..
26/12/202313:59GLOBE60 Degrees Pharma Announces IRB Approval of Phase IIA Study..
15/11/202313:29GLOBE60 Degrees Pharma Announces Type C Meeting with FDA to..
19/10/202314:31GLOBE60 Degrees Pharma to Present Review of Safety, Efficacy Data..
12/10/202322:16GLOBE60 Degrees Pharmaceuticals Suspends Phase IIB Study of..
18/9/202322:16GLOBE60 Degrees Pharma Withdraws COVID Phase IIB IND, Will..
06/9/202313:31GLOBE60 Degrees Pharmaceuticals to Participate in H.C. Wainwright..
30/8/202313:32GLOBE60 Degrees Pharmaceuticals Study Results Published by New..
22/8/202313:31GLOBE60 Degrees Pharmaceuticals Receives Additional U.S. Patent..
15/8/202313:31GLOBE60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB..
31/7/202313:59GLOBE60 Degrees Pharmaceuticals Awarded Canadian Patent Covering..
14/7/202319:30PRNUSWallachBeth Capital Announce Closing Of 60 Degrees..
14/7/202318:39GLOBE60 Degrees Pharmaceuticals Announces Closing of Initial..
12/7/202319:45PRNUSWallachBeth Capital Announce Pricing Of 60 Degrees..
12/7/202318:29GLOBE60 Degrees Pharmaceuticals Announces Pricing of Initial..

Dernières Valeurs Consultées

NASDAQ
SXTP
60 Degrees Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés